Action NOVNNOVARTIS AG
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Novartis AG

Actions

NOVN

CH0012005267

Produits pharmaceutiques

Marché Fermé - Swiss Exchange
Autres places de cotation
 17:31:31 17/04/2025 		Varia. 5j. Varia. 1 janv.
90,63 CHF +0,19% Graphique intraday de Novartis AG +5,27% +2,18%
19/04 NOVARTIS : les tensions tarifaires créent une bonne opportunité d'entrée sur le marché Alphavalue
18/04 Les entreprises envisagent de se développer aux États-Unis afin d'atténuer les retombées d'éventuels droits de douane RE

Communiqués

Recherche
Voir les résultats
Barbara Weber, M.D., Elected to ITM Supervisory Board
10/04
 AQ
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
03/04
 GL
CD Milan, March 27, 2025, Procedural Order On Application To Intervene, UPC_CFI_698/2024
02/04
 AQ
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
31/03
 GL
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
28/03
 GL
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
25/03
 GL
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
21/03
 GL
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
19/03
 GL
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
10/03
 AQ
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
07/03
 GL
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
28/02
 GL
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
28/02
 GL
Novartis : Earnings Document (novartis q4 2024 impact and sustainability update)
11/02
 PU
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
11/02
 GL
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
03/02
 AQ
Novartis: Q4 Earnings Snapshot
31/01
 AQ
Novartis : Earnings Document (2025 01 interim financial report en)
31/01
 PU
Novartis : Earnings Document (q4 2024 investor presentation)
31/01
 PU
Novartis : Earnings Document (q4 2024 investor presentation)
31/01
 PU
Novartis : Earnings Document (novartis integrated report 2024)
31/01
 PU
Novartis : Earnings Document (novartis annual report 2024)
31/01
 PU
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
31/01
 GL
Early detection is a game changer, Novartis makes bold play to prioritize breast health and inspire a new wave of breast cancer screenings
29/01
 AQ
Novartis Entresto US patent upheld by US Court of Appeals
15/01
 AQ
Novartis Entresto® US patent upheld by US Court of Appeals
13/01
 GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NOVN
  4. Actualités Novartis AG
  5. Communiqués
Etats-Unis

Zonebourse is also available in this country: United States.

Switch edition
Rester sur l'édition actuelle